THE RIGHT MEASURE?:

Validated patient-reported outcome measurements for psoriasis may not reflect patients’ current preferences

Oluwatobi A. Ogbechie-Godec, MD MBA
AAD Resident and Fellows Symposium
February 17, 2018

Jasmine Lee, BS; Sarah Azarchi, BS; David E. Cohen, MD; Andrea Neimann, MD; Arielle R. Nagler, MD
Disclosure of relationships with industry

Oluwatobi Ogbechie-Godec, MD

5670 Validated Patient-Reported Outcome Measurements for Psoriasis may not Reflect Patients’ Current Preferences

Disclosures

I do not have any relevant relationships with industry
Agenda

• Background
  • PROMs
  • Psoriasis-specific PROMs
  • AAD’s efforts on measures
• Methods
• Results
• Preliminary implications
• Next steps
Patient-reported outcome measures (PROMS) are being developed for reimbursement and value.

National Psoriasis Foundation: A Patient-Centric Approach to Improve Access to Psoriatic Disease Treatment

Author: Leah McCormick Howard, JD
Psoriasis-specific validated PROMs exist amidst the newer physician-reported measures

Many developed and validated PROMs in the literature

The AAD has developed physician-reported measures for psoriasis

Psoriasis-specific PRO measures

<table>
<thead>
<tr>
<th>AAD ID</th>
<th>MIPS/NQF ID</th>
<th>Measure name</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>06</td>
<td>MIPS 410</td>
<td>Psoriasis Clinical Response to Oral Systemic or Biologic Medications</td>
<td>Percentage of psoriasis patients receiving oral systemic or biologic therapy who meet minimal physician-or patient-reported disease activity levels. It is implied that establishment and maintenance of an established minimum level of disease control as measured by physician-and/or patient-reported outcomes will increase patient satisfaction with and adherence to treatment.</td>
</tr>
<tr>
<td>07</td>
<td>N/A</td>
<td>Psoriasis Assessment of Psoriasis Disease Activity</td>
<td>Percentage of patients with plaque psoriasis who have disease activity assessed by using one of the listed measures or validated instruments/tools at least once during the measurement period.</td>
</tr>
</tbody>
</table>

Research questions and methods

1. What outcomes measures are currently evaluated in the validated psoriasis-specific PROMs?
   - Literature review of psoriasis-specific PROMs
   - Categorization of outcome measures into 6 broader focus areas

2. What do patients with psoriasis currently consider when evaluating treatment options for their psoriasis?
   - Patient survey and chart review at a specialty clinic in an academic center mostly treating patients with moderate to severe psoriasis
     - 8-question patient survey
     - Chart review of medications and clinical assessment
1. Which factors are most important to you in selecting a treatment for psoriasis? (please rank from most important [1] to least important [6])

- Clearance (how much of my body still has psoriasis rash)
- Cost (how much do I pay for the treatment)
- Mood and Quality of Life (how does the treatment affect my mood and typical life activities)
- Symptoms (how much discomfort, like itching or pain, do I feel because of the psoriasis rash)
- Frequency of doctor visits (how often do I have to go to a doctor’s office or laboratory for treatment)
- Treatment form (what type of treatment [creams, injectables, pills, phototherapy] and side effects do I have)
18 existing psoriasis-specific focus on mood/quality of life and symptoms
Survey demographics to date

<table>
<thead>
<tr>
<th>Description</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total survey responses to date</td>
<td>46</td>
</tr>
<tr>
<td>Number of eligible responses</td>
<td>41</td>
</tr>
<tr>
<td>Number of unique subjects</td>
<td>39</td>
</tr>
<tr>
<td>Mean of age (standard deviation)</td>
<td>53.1 (15.6)</td>
</tr>
<tr>
<td>Number of unique males (females)</td>
<td>25 (14)</td>
</tr>
<tr>
<td>Number currently on oral systemics and/or biologics</td>
<td>31</td>
</tr>
<tr>
<td>Number currently on biologics</td>
<td>21</td>
</tr>
<tr>
<td>Number currently on monotherapy with topicals</td>
<td>8</td>
</tr>
<tr>
<td>Number on phototherapy</td>
<td>3</td>
</tr>
</tbody>
</table>
Preliminary data suggest that clearance and symptoms are the most important factors

Most important factors when considering treatment options

[Most important = 1, Least important = 6]
Preliminary implications

Most psoriasis-specific PROMs focus on mood and quality of life, but most patients report that clearance and symptoms are most important to them.

Cost of the treatment and frequency of visits are not as important to patients.

Value-based outcome measurements should incorporate patients’ concerns without penalizing dermatologists.
Next steps

- Continue collecting patient survey data
- Subgroup analysis based on current treatment and severity of the psoriasis
- Subgroup analysis based on the location of the psoriatic lesions
- Inquiry into whether the AAD’s developed physician-submitted measures can be converted into psoriasis PROMs
- Fostering conversation about how to develop flexible and timely patient-reported validated measures
References

1. CMS. CMS Quality Measure Development Plan: Supporting the Transition to the Merit-based Incentive Payment System (MIPS) and Alternative Payment Models (APMs). 2016;May 2, 2016.


THANK YOU

• Sarah Azarchi, BS
• Jasmine Lee, BS
• David E. Cohen, MD
• Andrea Neimann, MD
• Arielle R. Nagler, MD